Zelapar (selegiline): Reviews and patient testimonials


/static/themes-v3/default/images/default/opinion/traitement/intro.jpg?1720004028

Back Back to the list of medications

Medication indications

Zelapar

Adjunctive therapy in combination with levodopa (with a peripheral decarboxylase inhibitor) in the treatment of Parkinson's disease. Zelapar in combination with maximal levodopa therapy is indicated particularly in patients who experience fluctuations in their condition such as 'end-dose' type fluctuations, 'on-off' symptoms or other dyskinesias.

Zelapar may be used alone in early Parkinson's disease for symptomatic relief and/or to delay the need for levodopa.


Molecule: selegiline

Patients' opinions on Zelapar

In brief

General satisfaction level: Be the first to evaluate

Treatment's effectiveness: Be the first to evaluate

Ease of use: Be the first to evaluate

Adherence to prescription: Be the first to evaluate

Detected side effects: Be the first to evaluate

Improvement in the quality of life: Be the first to evaluate

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Never
10 = Always

1 = Not at all important
10 = Extremely important

1 = Not at all satisfied
10 = Extremely satisfied

Tips and advice of the community

Join Carenity and be the first to give your opinion on this medication.

Conditions related to this medication

Fact sheet

Parkinson's disease

See the fact sheet